San Francisco, CA. July 24, 2022 — Dr. Antoni Ribas, an immuno-oncology pioneer, has joined Vial’s Oncology Scientific Advisory Board. Dr. Ribas, along with other members of the board, will advise Vial on the launch of their upcoming Oncology CRO.
The Vial CRO’s mission is to reimagine clinical trials by delivering faster and higher quality trials through a powerful technology platform and operational excellence. Vial aims to be a true partner to biotech sponsors. To ensure recruitment timelines are met, Vial has built an enrollment playbook that offers a seamless web-based site start-up, a dedicated recruitment team, and EMR filtering capabilities to deliver potential subjects to a centralized pre-screen team. In addition, Vial’s experienced CRAs have the power of real-time data using eSource to drive defect-free processes and deliver high-quality data.
“I have devoted my career to the development of innovative Oncology therapies and I joined the Vial CRO advisory board to support the development of clinical trial infrastructure that enables scientists in advancing the field. I look forward to working with fellow Oncology investigators on the Vial SAB board to help Vial implement innovative approaches to Oncology clinical trials.” said Dr. Ribas on joining the board.
After gaining rapid traction with sponsors in other therapeutic areas, Vial has been working closely with Oncology sponsors to understand the true pain points in running trials and to build better solutions tailored to the unique needs of the Oncology clinical trial market. Earlier this year, Vial announced Dr. Arati Rao as the initial member of the Vial Oncology CRO Scientific Advisory Board.
Antoni Ribas, MD, Ph.D. serves as Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC), and the Chair of the Melanoma Committee at SWOG. Dr. Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene-engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors, and nanoparticle-siRNA. Dr. Ribas started his academic career at the University of Barcelona before pursuing postdoctoral research and fellowships at UCLA.
Dr. Ribas has been a pioneer in the field of cutting-edge Oncology therapeutics, notable in the clinical development of several agents approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist). He is an elected member of the American Society of Clinical Investigation (ASCI), the recipient of the AACR Richard and Hinda Rosenthal Award, and a National Cancer Institute (NCI) Outstanding Investigator Award.
About Vial: Vial’s mission is to empower scientists to cure all human diseases. Vial has executed that vision by launching a next-generation CRO (with slated launches in Ophthalmology CRO, Oncology CRO, Gastroenterology CRO, and a Neurology CRO), a site network (Dermatology Clinical Trials, Ophthalmology Clinical Trials, Gastroenterology Clinical Trials, Women’s Health Clinical Trials, Neurology Clinical Trials), and technology platform (VialConnect CTMS) to accelerate research. Vial has over 125 employees and is based in San Francisco, California, and has contributed to over 750 trials from Phase I through Phase IV.